

A causal inference study on the impact of asthma on the onset of chronic obstructive pulmonary disease: two-sample Mendelian randomization

Wusheng Liu^{1,2*}, YuHui Xu^{1,2}, Zanlei Zhu^{1,2}, ShiHao Zhang^{1,2}

¹Department of Respiratory and Critical Care Medicine, Ganzhou People's Hospital, Zhanggong, Ganzhou, Jiangxi, China

²The Affiliated Ganzhou Hospital, Jiang Xi Medical College, Nanchang University, Zhanggong, Ganzhou, Jiangxi, China

Submitted: 5 August 2024; Accepted: 3 December 2024

Online publication: 22 February 2025

Arch Med Sci 2025; 21 (5): 1925–1935

DOI: <https://doi.org/10.5114/aoms/196808>

Copyright © 2025 Termedia & Banach

***Corresponding author:**

Wusheng Liu
Department of Respiratory
and Critical Care Medicine
Ganzhou People's Hospital
The Affiliated Ganzhou
Hospital
Jiang xi Medical College
Nanchang University
No. 16, Meiguan Avenue
Zhanggong, Ganzhou
Jiangxi 341000, China

Abstract

Introduction: Asthma and chronic obstructive pulmonary disease (COPD) are two common respiratory ailments with an overlapping pathogenesis.

Material and methods: In this study, using a two-sample Mendelian randomization (MR) approach and analyzing publicly available genome-wide association study (GWAS) datasets, we explored the causal impact of asthma on the onset of COPD.

Results: Using genetic instrumental variables associated with asthma ($p < 5 \times 10^{-8}$) and applying multiple MR methods (IVW, MR-Egger, and weighted median), we identified a significant causal relationship between asthma and COPD. The inverse variance weighted (IVW) method indicated that asthma increases the risk of developing COPD with an odds ratio (OR) of 1.35 (95% confidence interval [CI]: 1.12–1.58, $p = 0.002$). Additionally, multivariable MR analysis was performed to account for potential confounders, such as eosinophil count, smoking, and falls, which demonstrated that the association remains significant even after adjusting for these factors (OR = 1.29, 95% CI: 1.08–1.50, $p = 0.004$).

Conclusions: This study provides robust evidence supporting the causal link between asthma and COPD, offering a more comprehensive understanding of their relationship.

Key words: asthma, genome-wide association study, Mendelian randomization, causal relationship, chronic obstructive pulmonary disease, environmental exposure factors.

Introduction

Respiratory diseases have long been a focus of research in the field of public health, posing a serious threat to the health of the global population [1]. Among them, asthma and chronic obstructive pulmonary disease (COPD) are two highly prevalent diseases, posing significant challenges to patients' quality of life and the consumption of social medical resources. Although asthma and COPD have distinct pathological and physiological differences, with the former mainly characterized by chronic airway inflammation and the latter encompassing pathological changes such as chronic bronchitis and emphysema, their relationship and mutual influence remain a scientific puzzle of great concern [2, 3].

Asthma manifests as a complex chronic inflammatory condition, featuring airway hyperresponsiveness and reversible airway obstruction. Hundreds of millions of people worldwide suffer from asthma, affecting both adults and children [4]. COPD mainly includes chronic bronchitis and emphysema, is a progressive disease commonly found in smokers, and is also influenced by environmental factors such as air pollution. Both diseases are primarily characterized by symptoms such as dyspnea, cough, and chest tightness, causing significant inconvenience to patients' lives and work [5].

Although asthma and COPD differ in presentation and progression, they share important common features. Studies have shown that in some patients, asthma and COPD may coexist, referred to as "asthma-COPD overlap syndrome" (ACOS) [6]. This situation complicates the management and treatment of the disease, making it even more necessary to investigate the relationship between asthma and COPD to better understand their shared pathophysiological mechanisms and provide more precise bases for treatment strategies [7].

Previous studies have mainly examined the pathogenesis and causative factors of asthma and COPD separately. Whether asthma may causally contribute to the development of COPD, however, remains unclear. Some observational studies have provided some clues, but due to the presence of numerous confounding factors, the research findings are contentious. Therefore, we need a more precise method to control for confounding variables.

By adopting a Mendelian randomization approach, which enables exploration of the causal relationship between asthma and COPD without being influenced by confounding factors, this study evaluated the possible association between the two conditions. Integrating publicly available genome-wide association study (GWAS) datasets and employing careful selection of genetic instrumental variables, alongside various Mendelian randomization analysis methods, the study sought to elucidate the genetic mechanisms underlying asthma and COPD, thereby providing a clearer understanding of their interrelation.

Material and methods

Guidelines for reporting and study design

This study used a two-sample MR approach and publicly available datasets to investigate the impact of asthma on COPD. The study report adheres to the STROBE-MR Statement, which enhances the reporting of observational studies in epidemiology using Mendelian randomization [8]. Figure 1 illustrates the study design schematically.

Data sources

Genome-wide association study (GWAS) data for preliminary analysis of asthma indicators were obtained from two studies: by Demenais *et al.* on 127,669 individuals of European ancestry, including 107,715 controls and 19,954 asthma cases [9]; and by Valette *et al.* on 408,442 individuals of European ancestry, including 352,255 controls and 56,167 asthma cases [10].

Chronic obstructive pulmonary disease (COPD) GWAS data (ebi-a-GCST90018807) were obtained from a study by Sakaue *et al.* on 468,475 individuals of European ancestry, including 13,530 COPD cases and 454,945 controls [11].

Other GWAS data: eosinophil cell count (ieu-b-33) from Vuckovic *et al.*, including 563,946 samples [12, 13]; past tobacco smoking (ukb-b-2134) [14] from approximately 500,000 UK Biobank samples [15]; falling risk (ebi-a-GCST90012857) from GWAS data analysis including 451,179 samples [16, 17].

Instrumental variable selection

Effective genetic instrumental variables must meet three core assumptions: (1) the relevance assumption, i.e., the chosen instrumental variables must exhibit a significant association with the exposure factor; (2) the independence assumption, i.e., instrumental variables must not be significantly correlated with potential confounding factors that might affect exposure or outcome; (3) the exclusion restriction assumption, i.e., instrumental variables must exclusively influence the outcome through the pathway "instrumental variable → exposure → outcome".

In this study, the selection criteria for exposure instrumental variables were as follows: single nucleotide polymorphisms (SNPs) with $p < 5 \times 10^{-8}$ in GWAS were used as the primary screening condition; SNPs in linkage disequilibrium ($r^2 < 0.001$) and with a physical distance $> 10,000$ kb between every two genes were excluded. Then, outcome data were extracted from GWAS based on the selected SNPs.

MR causal effect estimation

Various two-sample MR methods were used to assess the causal effects between exposure and outcome, including: inverse-variance weighted (IVW), MR-Egger, weighted median, simple mode, and weighted mode. Studies have shown [18] that the IVW method is slightly stronger under certain conditions than other methods. Its characteristic is that it does not consider the presence of intercept terms during regression and uses the reciprocal of the outcome variance as weights for fitting. Therefore, in the absence of pleiotropy, regardless of the presence or absence of heterogeneity, the

IVW method was used as the main MR analysis approach in this study, with the other four methods used as supplementary analyses (an IVW random effects model was used when heterogeneity was present). When pleiotropy was present, the MR-Egger method was used to calculate the results. The reverse causal effect was assessed using the same methods to examine the potential causal effect of the outcome on the exposure.

Sensitivity analysis

Various methods, including heterogeneity testing, pleiotropy testing, and leave-one-out testing, were used to perform sensitivity analysis on the analysis results, as follows:

(1) Heterogeneity testing: Cochran's Q test was used to assess heterogeneity among estimated values of each SNP. If Cochran's Q test was statistically significant, it indicated significant heterogeneity in the results, and the effect size of the causal effect was evaluated using the IVW random effects model. Since Cochran's Q test could only determine the presence or absence of heterogeneity and cannot determine its distribution, the I^2 statistic was used to reflect the proportion of heterogeneity in the total variation of instrumental variables: $I^2 \leq 0$ indicates no observed heterogeneity; $I^2 = 0$ –25% indicates mild heterogeneity; $I^2 = 25$ –50% indicates moderate heterogeneity; $I^2 > 50\%$ indicates high heterogeneity.

(2) Pleiotropy assessment: The MR-Egger method was employed to examine pleiotropy in instrumental variables. A MR-Egger's intercept p -value < 0.05 was considered evidence of substantial horizontal pleiotropy in genetic variation.

(3) Leave-one-out testing: The leave-one-out method was used to evaluate whether a single SNP affects the association between asthma and COPD by sequentially removing individual SNPs and calculating the MR results with the remaining instrumental variables. If there was a large difference between the MR effect estimate after removing a particular instrumental variable and the cumulative effect estimate, it indicated that the MR effect estimate was sensitive to that SNP.

Multivariable MR analysis

MVMR is an extension of MR that uses genetic variations associated with multiple exposures possibly correlated with a single outcome to evaluate the impacts of various exposures on a singular outcome. It could assess the direct effects of individual exposure factors on the outcome. We conducted multivariable MR analysis considering several COPD-related exposure factors – eosinophil cell count (ieu-b-33), past tobacco smoking (ukb-b-2134), falling risk (ebi-a-GCST90012857),

and asthma – to estimate the direct effect of asthma on COPD.

Statistical analysis

All data processing and statistical analyses were performed using the R programming language (version 4.2.2). Mendelian randomization analysis primarily relied on the TwoSampleMR package [19]. To ensure the robustness and reliability of the results, Cochran's Q test and leave-one-out analysis were used. Additionally, genetic pleiotropy was assessed using MR-Egger's intercept method. Evaluation metrics consisted of odds ratios (OR) and their corresponding 95% confidence intervals (95% CI). All statistical p -values were two-sided, with SNP loci generated from GWAS studies considered statistically significant at $p < 5 \times 10^{-8}$; statistical significance was determined for other tests at a threshold of $p < 0.05$.

Results

Analysis framework and flowchart

The flowchart is shown in Figure 1.

Instrumental variable selection

Based on the selection criteria for instrumental variables, SNPs with linkage disequilibrium were removed, and SNPs associated with asthma ($p < 5 \times 10^{-8}$, clump=TRUE, $r^2 < 0.001$, kb = 10,000) were included as instrumental variables after matching with COPD GWAS data.

MR causal effect estimation

Analysis was conducted using five models: MR Egger, weighted median, inverse variance weighted (IVW), simple mode (SM), and weighted mode. The results of the five models for the causal relationship between asthma and COPD (Figure 2 A, Table I) indicated a significant causal relationship between asthma and COPD, with higher levels of all circulating metabolites associated with an increased risk of COPD occurrence. Different models of MR analysis for asthma (Figures 2 B, C) provided consistent directional estimates, with relatively consistent slopes.

Sensitivity analysis

Heterogeneity testing of significant results was conducted using Cochran's Q test and I^2 statistic, as shown in Table II. The results indicated high heterogeneity in the Mendelian randomization (MR) results for asthma (id: ebi-a-GCST006862) with respect to COPD ($I^2 = 50.65\%$, Cochran Q p -value < 0.05). However, there was no significant heterogeneity in the MR results for asthma (id: ebi-a-




Figure 1. Mendelian randomization analysis flowchart. **A** – Basic assumptions of Mendelian randomization analysis, including (1) the relevance assumption, which states that selected instrumental variables must be significantly associated with the exposure factor; (2) the exclusion restriction assumption, which states that instrumental variables could only affect the outcome through the pathway “instrumental variable → exposure → outcome”; (3) the independence assumption, which states that instrumental variables must not be significantly correlated with potential confounding factors that might affect exposure or outcome. **B** – Flowchart of the analysis methods used in this study

SNP – single nucleotide polymorphism. IVW – inverse variance weighted. MR-Egger – Mendelian randomization-Egger. GWAS – genome-wide association study.

GCST90014325) with respect to COPD (Cochran Q p -value > 0.05 , $I^2 < 50\%$). The exposure of asthma (id: ebi-a-GCST006862) with high heterogeneity was removed, and the exposure of asthma (id: ebi-a-GCST90014325) was analyzed further. The funnel plot of instrumental variables for asthma (id: ebi-a-GCST90014325) (Figure 3 A) showed a symmetrical distribution of scatter points, indicating no potential bias in the causal association effect.

Instrumental variable horizontal pleiotropy testing was conducted using MR-Egger regression. The p -value of the intercept term in the statistical hypothesis test for the p -value associated with asthma (id: ebi-a-GCST90014325) exceeded 0.05, and the intercept value approached zero, indicat-

ing that the causal inference of this study was not affected by horizontal pleiotropy (Table III).

We performed leave-one-out analysis, systematically excluding each instrumental variable locus, to examine the causal impact of asthma on COPD (Figure 3 B). It was found that there was no significant deviation from the total effect of the instrumental variable set. The Steiger directional test result confirmed the causal direction with a p -value less than 0.05, indicating no reverse causal effect (Table IV).

Reverse MR analysis

To evaluate reverse causal effects, we used COPD as the exposure and asthma (id: ebi-a-

A

Exposure	Method	β	OR (95% CI)	P-value
Asthma (ebi-a-GCST90014325)	Inverse variance weighted	0.3671981	1.44 (1.36, 1.53)	9.99e-35
Asthma (ebi-a-GCST90014325)	MR Egger	0.3407018	1.41 (1.21, 1.63)	3.12e-05
Asthma (ebi-a-GCST90014325)	Simple mode	0.2518579	1.29 (1.06, 1.56)	0.0128
Asthma (ebi-a-GCST90014325)	Weighted median	0.3698692	1.45 (1.33, 1.57)	7.18e-18
Asthma (ebi-a-GCST90014325)	Weighted mode	0.3482749	1.42 (1.23, 1.63)	7.78e-06
Asthma (ebi-a-GCST006862)	Inverse variance weighted	0.3022835	1.35 (1.25, 1.46)	4.72e-15
Asthma (ebi-a-GCST006862)	MR Egger	0.2120904	1.24 (0.95, 1.61)	0.134
Asthma (ebi-a-GCST006862)	Simple mode	0.2493573	1.28 (1.09, 1.51)	0.00841
Asthma (ebi-a-GCST006862)	Weighted median	0.2704959	1.31 (1.20, 1.43)	1.97e-09
Asthma (ebi-a-GCST006862)	Weighted mode	0.2546926	1.29 (1.13, 1.47)	0.00149



B**C**

Figure 2. Multiple model analysis results of Mendelian randomization analysis for asthma and chronic obstructive pulmonary disease. **A** – Forest plot showing the causal association analysis results of Mendelian randomization using multiple models for asthma and chronic obstructive COPD. Effect estimates are presented using OR and 95% CI, along with the number of instrumental variables used in each model, as well as the calculated beta values and standard errors. **B, C** – Scatter plots showing the causal relationship between asthma (id: ebi-a-GCST006862) (**B**), asthma (id: ebi-a-GCST90014325) (**C**), and chronic obstructive pulmonary disease. The slope of the line represents the magnitude of the causal relationship predicted by different models

SNPs – single nucleotide polymorphisms, OR – odds ratio, CI – confidence interval.

Table I. Estimates of Mendelian randomized causal effects of asthma and chronic obstructive pulmonary disease

Exposure	Method	Number of SNPs	β	Standard error	P-value	OR
Asthma (ebi-a-GCST90014325)	Inverse variance weighted	65	0.367198137	0.02987265	9.99E-35	1.44 (1.36, 1.53)
Asthma (ebi-a-GCST90014325)	MR Egger	65	0.340701751	0.075904004	3.12E-05	1.41 (1.21, 1.63)
Asthma (ebi-a-GCST90014325)	Simple mode	65	0.251857948	0.09838223	0.0128	1.29 (1.06, 1.56)
Asthma (ebi-a-GCST90014325)	Weighted median	65	0.369869234	0.042948228	7.18E-18	1.45 (1.33, 1.57)
Asthma (ebi-a-GCST90014325)	Weighted mode	65	0.348274863	0.071580068	7.78E-06	1.42 (1.23, 1.63)
Asthma (ebi-a-GCST006862)	Inverse variance weighted	18	0.302283474	0.038585381	4.72E-15	1.35 (1.25, 1.46)
Asthma (ebi-a-GCST006862)	MR Egger	18	0.21209039	0.134307392	0.134	1.24 (0.95, 1.61)
Asthma (ebi-a-GCST006862)	Simple mode	18	0.2493573	0.083676473	0.00841	1.28 (1.09, 1.51)
Asthma (ebi-a-GCST006862)	Weighted median	18	0.270495937	0.045079563	1.97E-09	1.31 (1.20, 1.43)
Asthma (ebi-a-GCST006862)	Weighted mode	18	0.254692559	0.067375612	0.00149	1.29 (1.13, 1.47)

SNPs – single nucleotide polymorphisms, OR – odds ratio, CI – confidence interval.

Table II. Mendelian randomization analysis heterogeneity test for the association between asthma and chronic obstructive pulmonary disease




Table III. Mendelian randomization analysis of horizontal pleiotropy for the association between asthma and chronic obstructive pulmonary disease

SNP – single nucleotide polymorphism, r^2 – proportion of variance explained.

GCST90014325) as the outcome. Following the selection criteria for instrumental variables in this study and removing SNPs with linkage disequilibrium, the reverse causal MR analysis results (Figure 4) indicated that COPD did not have a significant causal effect on asthma ($p > 0.05$), as shown in Table V.

Multivariable MR analysis

We conducted multivariable MR analysis by incorporating exposures such as eosinophil cell count

(ieu-b-33), past tobacco smoking (ukb-b-2134), falling risk (ebi-a-GCST90012857), etc., to assess the direct effect of asthma (ebi-a-GCST90014325) on COPD (Table VI). In Model 1, correcting for the indirect effect of eosinophil cell count, the results indicated that asthma (ebi-a-GCST90014325) still significantly affects COPD. In Model 2, correcting for the influence of smoking, the results showed that asthma (ebi-a-GCST90014325) still significantly affects COPD. In Model 3, considering the




Figure 4. Multiple model analysis results of reverse causal Mendelian randomization analysis for chronic obstructive pulmonary disease and asthma. The forest plot presents the results of reverse causal association analysis between COPD and asthma using multiple Mendelian randomization models. Effect estimates are displayed using OR and 95% CI, along with the number of instrumental variables used in each model, as well as the calculated beta values and standard errors

SNPs – single nucleotide polymorphisms, OR – odds ratio, CI – confidence interval.

Table V. Results of reverse causal Mendelian randomization analysis of chronic obstructive pulmonary disease and asthma

Exposure	Outcome	Method	Number of SNPs	β	Standard error	P-value
Chronic obstructive pulmonary disease	Asthma (ebi-a-GCST90014325)	MR Egger	10	-0.136972222	0.092977815	0.178926771
Chronic obstructive pulmonary disease	Asthma (ebi-a-GCST90014325)	Weighted median	10	0.003900208	0.027606237	0.88764878
Chronic obstructive pulmonary disease	Asthma (ebi-a-GCST90014325)	Inverse variance weighted	10	0.055008497	0.046306146	0.234860669
Chronic obstructive pulmonary disease	Asthma (ebi-a-GCST90014325)	Simple mode	10	0.017520151	0.04379152	0.698426597
Chronic obstructive pulmonary disease	Asthma (ebi-a-GCST90014325)	Weighted mode	10	0.004347437	0.025058646	0.866105254

SNPs – single nucleotide polymorphisms.

impact of falling risk, the results demonstrated that asthma (ebi-a-GCST90014325) still significantly affects COPD.

Discussion

This study evaluated into the causal impact of asthma on COPD through a two-sample Mendelian randomization design. Firstly, by rigorously screening publicly available GWAS data, we successfully selected a series of SNPs that meet the criteria for instrumental variables for subsequent causal effect estimation. Through various two-sample MR methods, we concluded that asthma serves as a significant risk factor for COPD, providing solid genetic evidence for further elucidating the relationship between these two diseases.

In sensitivity analysis, we validated the robustness of the results through methods such as heterogeneity testing and pleiotropy testing. Even after excluding SNPs with high heterogeneity, the results remained significant. Through leave-one-out analysis, we further confirmed the robustness of the instrumental variables, eliminating the sig-

nificant influence of individual SNPs on the overall outcomes. The results of the MR-Egger intercept method also indicate that the causal inference of this study is not significantly affected by horizontal pleiotropy.

To gain a more comprehensive understanding of the impact of asthma on COPD, we conducted reverse MR analysis and found that COPD does not have a significant causal effect on asthma, thereby ruling out the possibility of reverse causality.

Finally, through multivariable MR analysis, we explored the impact of multiple potential confounding factors on the relationship between asthma and COPD. The results indicate that the causal effect of asthma on COPD still exists after considering factors such as eosinophil cell count, smoking, and falling risk.

Previous research in the asthma and COPD field had extensively explored their pathogenesis, pathophysiological processes, and their relationship with environmental, genetic, and other factors. However, the relationship between asthma

Table VI. Results of multivariable Mendelian randomization analysis on the impact of asthma and chronic obstructive pulmonary disease

Model	Exposure	Outcome	SNPs	Beta	SE	P-value	OR (95% CI)
Model 1	Eosinophil cell count	Chronic obstructive pulmonary disease	398	0.037394501	0.03433414	0.276094521	1.038 (0.971, 1.110)
	Asthma	Chronic obstructive pulmonary disease	34	0.362836557	0.036274363	1.49E-23	1.437 (1.339, 1.543)
Model 2	Past tobacco smoking	Chronic obstructive pulmonary disease	77	-0.737199808	0.087208236	2.83E-17	0.478 (0.403, 0.568)
	Asthma	Chronic obstructive pulmonary disease	64	0.37334249	0.029146487	1.46E-37	1.453 (1.372, 1.538)
Model 3	Falling risk	Chronic obstructive pulmonary disease	2	0.117250627	0.228771877	0.608285706	1.124 (0.718, 1.761)
	Asthma	Chronic obstructive pulmonary disease	70	0.366839717	0.028134419	7.36E-39	1.443 (1.366, 1.525)

Model 1: Multivariable MR analysis of asthma and eosinophil cell count on chronic obstructive pulmonary disease; Model 2: Multivariable MR analysis of asthma and past tobacco smoking on chronic obstructive pulmonary disease; Model 3: Multivariable MR analysis of asthma and falling risk on chronic obstructive pulmonary disease. MR – Mendelian randomization, SNPs – single nucleotide polymorphisms.

and COPD has always been a contentious issue. Here are some key points and findings from previous studies: Previous research in the asthma and COPD field had extensively explored their pathogenesis, pathophysiological processes, and their relationship with environmental, genetic, and other factors. For instance, recent studies, such as the one by Kurmi *et al.* [20], have also investigated the genetic links and shared risk factors between these diseases, further supporting the potential overlap in their etiology. However, the relationship between asthma and COPD remains a contentious issue.

Traditionally, asthma and COPD were considered to be two diseases with distinct biological characteristics [21]. Asthma mainly involves airway inflammation and reversible airway obstruction, while COPD includes chronic bronchitis and emphysema, characterized by irreversible airway narrowing [22]. However, recent studies suggest that some patients might have both asthma and COPD, leading to asthma-COPD overlap syndrome (ACOS), with symptoms and biomarkers showing overlapping features, thereby increasing attention to the relationship between the two [23].

Early observational studies attempted to reveal the relationship between asthma and COPD but faced challenges due to confounding factors. For example, smoking, air pollution, occupational expo-

sure, etc., are factors that affect respiratory health, making it difficult for observational studies to establish whether asthma directly leads to the development of COPD [24]. In recent years, advances in techniques such as genome-wide association studies (GWAS) have enriched our comprehension of the genetic underpinnings of respiratory disorders. Some genes have been confirmed to be associated with asthma and COPD, but their specific mechanisms and their interrelationship remain uncertain.

In clinical practice, distinguishing between asthma and COPD is sometimes not straightforward, especially in some elderly patients or long-term smokers. The presence of this overlapping pathological state increases the difficulty of disease management [25].

Additionally, the understanding of asthma-COPD overlap syndrome (ACOS) remains incomplete, necessitating further research to elucidate the nature of this dual pathological state.

Our study contributes to this discussion by providing evidence that asthma is a risk factor for COPD development. To further understand the mechanisms involved, exploring how asthma-related factors influence COPD onset is crucial. Given the overlap of symptoms in ACOS and the inconclusive findings from previous observational studies, our study stands out by utilizing genetic evidence from GWAS to establish a caus-

al relationship between asthma and COPD. Additionally, our results emphasize the importance of addressing asthma control to potentially prevent COPD progression. Future research directions may involve studying specific asthma-related genetic markers and their impact on COPD development, as well as implementing personalized therapeutic interventions based on genetic susceptibility analysis. Overall, our study highlights the significance of recognizing asthma as a contributing factor to COPD and underscores the necessity for targeted interventions to alleviate disease burden and improve patient outcomes.

When discussing how asthma affects COPD and its implications for disease prevention or treatment, several mechanisms may be relevant. Firstly, the regulation of inflammation has a potential key role. Both asthma and COPD are associated with the inflammatory response, so studying the mechanism of inflammation regulation, such as reducing airway inflammation through medication or biological treatment, may prevent or treat the progression of COPD [26]. Further research may focus on developing novel inflammation-regulating agents and evaluating their effectiveness and safety in clinical practice. Secondly, the airway remodeling mechanism is also an important research direction. Asthma and COPD patients have abnormal airway structure and function; hence, studying the mechanism of airway remodeling and attempting to restore normal airway structure and function through medication or other treatment methods may help prevent or treat COPD [27]. Further research may include the development of novel treatment methods targeting airway remodeling and the evaluation of their long-term effects on COPD patients. Lastly, the immune regulation mechanism may also be a promising treatment approach. The immune system plays an important role in the development of asthma and COPD, so studying the mechanism of immune response regulation, such as the use of immunomodulators, may help prevent or treat COPD [28]. Further research may include the evaluation of the effectiveness and safety of different types of immunomodulators and the determination of the optimal treatment strategy. These potential mechanisms require further research to promote their application in disease prevention or treatment. Such research may encompass basic scientific investigations, including mechanism studies and drug development, as well as clinical research, such as clinical trials and epidemiological studies, to evaluate the effectiveness and safety of these mechanisms and determine the optimal treatment strategies. Additionally, interdisciplinary cooperation is needed to promote joint efforts from different fields of

expertise and accelerate the application of these mechanisms in clinical practice.

In addition to genetic factors, immune pathways play a significant role in the development of both asthma and COPD. Recent studies have highlighted the importance of Th17 cells and the IL-31/IL-33 axis in modulating chronic inflammation and immune responses, which are pivotal in the pathogenesis of these diseases. Furthermore, factors such as vitamin D and the microbiome have been shown to influence immune regulation, potentially impacting disease progression. For example, recent work by Murdaca *et al.* [29] discussed these mechanisms in the context of chronic immune-mediated diseases, offering new insights into their therapeutic potential.

This study is innovative in its genetic approach, using Mendelian randomization methods to minimize confounding factors, and evaluating whether asthma directly affects the risk of COPD. This will help fill the gaps in existing research and provide new directions for future studies. Additionally, through multivariable MR analysis, we will explore the impact of other exposure factors related to COPD, thereby achieving a more comprehensive understanding of this complex disease relationship.

In summary, this study provides new genetic evidence and theoretical support for understanding the relationship between asthma and COPD through comprehensive analysis from multiple perspectives and methods. This has positive implications for the formulation of preventive and therapeutic strategies for related diseases and the selection of future genetic research directions.

In this study, there are limitations that need to be considered. Firstly, despite our efforts to screen publicly available GWAS data rigorously, the limited nature of the data prevents us from conducting detailed analyses on more disease pathological types. Particularly, due to the scarcity of patients and the lack of specific SNP data, we cannot confirm the relationship between asthma and certain specific pathological types of COPD. Additionally, due to the diversity of “exposure” sources and the lack of relevant SNP data, we have yet to investigate whether specific sources of “exposure” exert similar biological effects on diseases and whether “exposure” has a consistent impact across different subgroups. It is worth noting that our data primarily consist of samples of European ancestry, and thus, may not adequately differentiate ethnic variations from various regions, potentially limiting the generalizability of these results to a global scale. Although the data from GWAS or large samples used for diseases are continuously increasing, there remains a problem of data insufficiency. Further ex-

ploration of the basic multicenter research mechanisms between “exposure” and “outcome” is needed to better understand how asthma affects the occurrence and development of COPD.

In conclusion, our research findings suggest that there is a significant causal relationship between asthma and COPD, indicating that the occurrence of asthma increases the likelihood of COPD developing in patients. Even when considering potential confounding factors, asthma still exerts a significant causal effect on COPD. These findings deepen our understanding of the association between COPD and asthma, providing an important reference for further research and clinical practice. Future studies should further explore the complex relationship between these two diseases to promote the development of prevention and treatment strategies for respiratory system diseases.

Availability of data and materials

Data and materials are available from <https://www.eqtngen.org/> and the corresponding GWAS consortium.

Funding

No external funding.

Ethical approval

Not applicable.

Conflict of interest

The authors declare no conflict of interest.

References

- GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Respir Med* 2020; 8: 585-96.
- Long B, Rezaie SR. Evaluation and management of asthma and chronic obstructive pulmonary disease exacerbation in the emergency department. *Emerg Med Clin North Am* 2022; 40: 539-63.
- Forno E, Ortega VE, Celedón JC. Asthma and chronic obstructive pulmonary disease. *Clin Chest Med* 2023; 44: 519-30.
- Ayakannu R, Abdullah NA, Radhakrishnan AK, Raj VL, Liam CK. Relationship between various cytokines implicated in asthma. *Hum Immunol* 2019; 80: 755-63.
- Upadhyay P, Wu CW, Pham A, et al. Animal models and mechanisms of tobacco smoke-induced chronic obstructive pulmonary disease (COPD). *J Toxicol Environ Health B Crit Rev* 2023; 26: 275-305.
- Fouka E, Papaioannou AI, Hillas G, Steiropoulos P. Asthma-COPD Overlap Syndrome: Recent Insights and Unanswered Questions. *J Pers Med* 2022; 12: 708.
- Hikichi M, Hashimoto S, Gon Y. Asthma and COPD overlap pathophysiology of ACO. *Allergol Int* 2018; 67: 179-86.
- Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. *BMJ* 2021; 375: n2233.
- Demenais F, Margaritte-Jeannin P, Barnes KC, et al. Multi-ancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. *Nat Genet* 2018; 50: 42-53.
- Valette K, Li Z, Bon-Baret V, et al. Prioritization of candidate causal genes for asthma in susceptibility loci derived from UK Biobank. *Commun Biol* 2021; 4: 700.
- Sakaue S, Kanai M, Tanigawa Y, et al. A cross-population atlas of genetic associations for 220 human phenotypes. *Nat Genet* 2021; 53: 1415-24.
- Kurki MI, Karjalainen J, Palta P, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. *Nature* 2023; 613: 508-18.
- Han Z, Hu H, Yang P, et al. White blood cell count and chronic obstructive pulmonary disease: a Mendelian randomization study. *Comput Biol Med* 2022; 151: 106187.
- Sakornsakolpat P, Prokopenko D, Maxime Lamon-tagne M, et al. Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. *Nat Genet* 2019; 51: 494-505.
- Rusk N. The UK Biobank. *Nat Methods* 2018; 15: 1001.
- Trajanoska K, Seppala LJ, Medibna-Gomez C, et al. Genetic basis of falling risk susceptibility in the UK Biobank Study. *Commun Biol* 2020; 3: 543.
- Oliveira CC, Annoni R, Lee AL, et al. Falls prevalence and risk factors in people with chronic obstructive pulmonary disease: a systematic review. *Respir Med* 2021; 176: 106284.
- Bowden J, Smith GD, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. *Genet Epidemiol* 2016; 40: 304-14.
- Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. *Elife* 2018; 7: e34408.
- Matujto-Balcerska E, Sipowicz K, Pietras T. Comparing chronic obstructive pulmonary disease and depressive disorder in terms of inflammation-related biomarkers. *Arch Med Sci* 2023; 19: 814-9.
- Lalas A, Nousias S, Kikidis D, et al. Substance deposition assessment in obstructed pulmonary system through numerical characterization of airflow and inhaled particles attributes. *BMC Med Inform Decis Mak* 2017; 17 (Suppl 3): 173.
- Park SY, Jung H, Kim JH, et al. Longitudinal analysis to better characterize asthma-COPD overlap syndrome: findings from an adult asthma cohort in Korea (COREA). *Clin Exp Allergy* 2019; 49: 603-14.
- Marron RM, Vega Sanchez ME. Asthma-COPD overlap syndrome. *Chronic Obstr Pulm Dis* 2019; 6: 200-2.
- Holtjer JCS, Bloemsma LD, Beijers RJHCG, et al. Identifying risk factors for COPD and adult-onset asthma: an umbrella review. *Eur Respir Rev* 2023; 32: 230009.
- Dey S, Eapen MS, Chia C, et al. Pathogenesis, clinical features of asthma COPD overlap, and therapeutic modalities. *Am J Physiol Lung Cell Mol Physiol* 2022; 322: L64-83.
- Van Eeckhoutte HP, Donovan C, Kim RY. RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD. *Eur Respir J* 2023; 61: 2201506.

27. Varricchi G, Ferri S, Pepys J, et al. Biologics and airway remodeling in severe asthma. *Allergy* 2022; 77: 3538-52.
28. Zhang Y, Xia R, Lv M, et al. Machine-learning algorithm-based prediction of diagnostic gene biomarkers related to immune infiltration in patients with chronic obstructive pulmonary disease. *Front Immunol* 2022; 13: 740513.
29. Murdaca G, Tagliafico L, Page E, et al. Gender differences in the interplay between vitamin D and microbiota in allergic and autoimmune diseases. *Biomedicines* 2024; 12: 1023.